FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2606235304> ?p ?o ?g. }

• W2606235304 endingPage "1471" @default.
• W2606235304 startingPage "1471" @default.
• W2606235304 abstract "Decitabine is reported to be valuable in treating multiple malignant blood diseases. However, the application of decitabine in myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML) has not been fully examined. Thus, our study aimed to investigate the clinical efficacy and safety of decitabine in treating such patients.Clinical data of MDS or AML patients treated with decitabine were retrospectively analyzed. All the patients were regularly followed up, and the risk factors affecting clinical efficacy were also detected.A total of 36 patients (MDS, n = 27; AML, n = 9) were included in the study. The response rate of MDS patients was 55%, and there were three cases (15%) of complete remission (CR), three cases (15%) of marrow CR, and five cases (15%) of hematologic improvement. It was about three cycles to achieve the best efficiencies. Gender, age, percentage of blasts in bone marrow, International Prognostic Scoring System risk group, and cytogenetic factors were not associated with response rate. The median overall survival of MDS patients was 8 (1-44) months. Agranulocytosis (P = 0.037) and severe anemia (P = 0.044) were the independent factors for prognosis. The complete response rate of AML was 33.3%. From the investigation, infection was the most common complication in our cohort, especially lung infection with the incidence of 27.8%.Our data demonstrated that decitabine was effective and relatively safe in treating MDS and AML. Patients with agranulocytosis and severe anemia were prone to have poor survival, which should be monitored in clinical practice." @default.
• W2606235304 created "2017-04-28" @default.
• W2606235304 creator A5002218874 @default.
• W2606235304 creator A5005282251 @default.
• W2606235304 creator A5009702306 @default.
• W2606235304 creator A5015568621 @default.
• W2606235304 creator A5024814292 @default.
• W2606235304 creator A5025398712 @default.
• W2606235304 creator A5041855727 @default.
• W2606235304 creator A5044044080 @default.
• W2606235304 creator A5045435034 @default.
• W2606235304 creator A5057887365 @default.
• W2606235304 creator A5062071376 @default.
• W2606235304 creator A5073000374 @default.
• W2606235304 creator A5086443370 @default.
• W2606235304 date "2019-01-01" @default.
• W2606235304 modified "2023-10-15" @default.
• W2606235304 title "Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia" @default.
• W2606235304 cites W1879966002 @default.
• W2606235304 cites W1976961324 @default.
• W2606235304 cites W1984814872 @default.
• W2606235304 cites W2010287588 @default.
• W2606235304 cites W2016419012 @default.
• W2606235304 cites W2019163316 @default.
• W2606235304 cites W2022240113 @default.
• W2606235304 cites W2022572639 @default.
• W2606235304 cites W2029595590 @default.
• W2606235304 cites W2034160841 @default.
• W2606235304 cites W2035169244 @default.
• W2606235304 cites W2040257851 @default.
• W2606235304 cites W2054060377 @default.
• W2606235304 cites W2081279521 @default.
• W2606235304 cites W2086492419 @default.
• W2606235304 cites W2106292925 @default.
• W2606235304 cites W2106584820 @default.
• W2606235304 cites W2129510594 @default.
• W2606235304 cites W2140587516 @default.
• W2606235304 cites W2160141443 @default.
• W2606235304 cites W2168387971 @default.
• W2606235304 cites W2169007954 @default.
• W2606235304 cites W2556086454 @default.
• W2606235304 cites W34668368 @default.
• W2606235304 doi "https://doi.org/10.4103/0973-1482.204849" @default.
• W2606235304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31939424" @default.
• W2606235304 hasPublicationYear "2019" @default.
• W2606235304 type Work @default.
• W2606235304 sameAs 2606235304 @default.
• W2606235304 citedByCount "5" @default.
• W2606235304 countsByYear W26062353042020 @default.
• W2606235304 countsByYear W26062353042021 @default.
• W2606235304 countsByYear W26062353042022 @default.
• W2606235304 countsByYear W26062353042023 @default.
• W2606235304 crossrefType "journal-article" @default.
• W2606235304 hasAuthorship W2606235304A5002218874 @default.
• W2606235304 hasAuthorship W2606235304A5005282251 @default.
• W2606235304 hasAuthorship W2606235304A5009702306 @default.
• W2606235304 hasAuthorship W2606235304A5015568621 @default.
• W2606235304 hasAuthorship W2606235304A5024814292 @default.
• W2606235304 hasAuthorship W2606235304A5025398712 @default.
• W2606235304 hasAuthorship W2606235304A5041855727 @default.
• W2606235304 hasAuthorship W2606235304A5044044080 @default.
• W2606235304 hasAuthorship W2606235304A5045435034 @default.
• W2606235304 hasAuthorship W2606235304A5057887365 @default.
• W2606235304 hasAuthorship W2606235304A5062071376 @default.
• W2606235304 hasAuthorship W2606235304A5073000374 @default.
• W2606235304 hasAuthorship W2606235304A5086443370 @default.
• W2606235304 hasBestOaLocation W26062353041 @default.
• W2606235304 hasConcept C104317684 @default.
• W2606235304 hasConcept C120665830 @default.
• W2606235304 hasConcept C121332964 @default.
• W2606235304 hasConcept C126322002 @default.
• W2606235304 hasConcept C143998085 @default.
• W2606235304 hasConcept C150194340 @default.
• W2606235304 hasConcept C185592680 @default.
• W2606235304 hasConcept C190727270 @default.
• W2606235304 hasConcept C2778248108 @default.
• W2606235304 hasConcept C2778461978 @default.
• W2606235304 hasConcept C2778729363 @default.
• W2606235304 hasConcept C2780007613 @default.
• W2606235304 hasConcept C2780235182 @default.
• W2606235304 hasConcept C2780240888 @default.
• W2606235304 hasConcept C2780817109 @default.
• W2606235304 hasConcept C55493867 @default.
• W2606235304 hasConcept C61511704 @default.
• W2606235304 hasConcept C71924100 @default.
• W2606235304 hasConceptScore W2606235304C104317684 @default.
• W2606235304 hasConceptScore W2606235304C120665830 @default.
• W2606235304 hasConceptScore W2606235304C121332964 @default.
• W2606235304 hasConceptScore W2606235304C126322002 @default.
• W2606235304 hasConceptScore W2606235304C143998085 @default.
• W2606235304 hasConceptScore W2606235304C150194340 @default.
• W2606235304 hasConceptScore W2606235304C185592680 @default.
• W2606235304 hasConceptScore W2606235304C190727270 @default.
• W2606235304 hasConceptScore W2606235304C2778248108 @default.
• W2606235304 hasConceptScore W2606235304C2778461978 @default.
• W2606235304 hasConceptScore W2606235304C2778729363 @default.
• W2606235304 hasConceptScore W2606235304C2780007613 @default.
• W2606235304 hasConceptScore W2606235304C2780235182 @default.

• next